Faron Pharmaceuticals Oy (FRA:4FR) Intangible Assets: €1.12 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
32 GF Score
Price €0.46
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Intangible Assets?

Faron Pharmaceuticals Oy FRA:4FR -2.82% 32 Intangible Assets is €1.12 Mil as of Dec. 2025. GuruFocus rates FRA:4FR with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Faron Pharmaceuticals Oy's intangible assets for the quarter that ended in Dec. 2025 was €1.12 Mil.


Faron Pharmaceuticals Oy  (FRA:4FR) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Faron Pharmaceuticals Oy Intangible Assets Related Terms


Faron Pharmaceuticals Oy Intangible Assets Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Intangible Assets Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.15 1.09 1.11 1.12

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.09 1.11 1.11 1.12
FRA:4FR
32GF Score
Faron Pharmaceuticals Oy FRA:4FR
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of €1.12 Mil mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a Intangible Assets of €1.12 Mil as of Dec. 2025. Intangible assets include patents, goodwill and trade secrets. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Intangible Assets too high?
Faron Pharmaceuticals Oy's current Intangible Assets is €1.12 Mil. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Intangible Assets compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Intangible Assets of €1.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Intangible Assets is €1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current Intangible Assets of €1.12 Mil. The current Intangible Assets is €1.12 Mil. Faron Pharmaceuticals Oy's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current Intangible Assets is €1.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
32GF Score

Get the complete analysis for FRA:4FR

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.46
Price